Stay updated with breaking news from Regenxbio inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
REGENXBIO Inc. (NASDAQ:RGNX – Get Free Report) has been given a consensus rating of “Moderate Buy” by the seven research firms that are covering the company, Marketbeat.com reports. Three analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price objective among […] ....
Adverum Biotechnologies' Ixo-vec gene therapy for wet AMD. Preliminary LUNA Phase 2 trial data show safety, efficacy, and significant treatment burden reduction. ....
Results support BLA submission in 2024 using the accelerated approval pathway Primary endpoint of patients achieving reduction in CSF biomarker of MPS II. ....
Regenxbio (RGNX) Announces Pivotal Trial of RGX-121 for the Treatment of MPS II Achieves Primary Endpoint streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.